Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication

British Journal of Haematology

Volumn 141, Issue 4, 2008, Pages 454-460

  Mead, Adam J ^a   Gale, Rosemary E ^a   Kottaridis, Panagiotis D ^a   Matsuda, Satomi ^a   Khwaja, Asim ^a   Linch, David C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acute myeloid leukaemia; fms like tyrosine kinase 3 (FLT3); Lestaurtinib; Mutation; Tyrosine kinase

Indexed keywords

CD135 ANTIGEN; CYTARABINE; LESTAURTINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAZOLES; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TANDEM REPEAT SEQUENCES;

EID: 42249113319     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07025.x     Document Type: Article

References (29)

1. Armstrong, S.A., Kung, A.L., Mabon, M.E., Silverman, L.B., Stam, R.W., Den Boer, M.L., Pieters, R., Kersey, J.H., Sallan, S.E., Fletcher, J.A., Golub, T.R., Griffin, J.D. Korsmeyer, S.J. (2003) Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell, 3, 173 183.
2. Brown, P., Meshinchi, S., Levis, M., Alonzo, T.A., Gerbing, R., Lange, B., Arceci, R. Small, D. (2004) Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood, 104, 1841 1849.
3. Caligiuri, M.A., Briesewitz, R., Yu, J., Wang, L., Wei, M., Arnoczky, K.J., Marburger, T.B., Wen, J., Perrotti, D., Bloomfield, C.D. Whitman, S.P. (2007) Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood, 110, 1022 1024.
4. Chou, T.C. Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27 55.
5. Choudhary, C., Schwable, J., Brandts, C., Tickenbrock, L., Sargin, B., Kindler, T., Fischer, T., Berdel, W.E., Muller-Tidow, C. Serve, H. (2005) AML-associated Flt3 kinase domain mutations show signal transduction differences in comparison to Flt3 ITD mutations. Blood, 106, 265 273.
6. Dicker, F., Haferlach, C., Kern, W., Haferlach, T. Schnittger, S. (2007) Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3-expression in acute myeloid leukemia. Blood, 110, 1308 1316.
7. Gale, R.E., Hills, R., Kottaridis, P.D., Srirangan, S., Wheatley, K., Burnett, A.K. Linch, D.C. (2005) No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood, 106, 3658 3665.
8. Gilliland, D.G. Griffin, J.D. (2002) Role of FLT3 in leukemia. Current Opinion in Hematology, 9, 274 281.
9. Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J. Saxena, K. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Molecular Cell, 13, 169 178.
10. Grundler, R., Miething, C., Thiede, C., Peschel, C. Duyster, J. (2005) FLT3-ITD and tyrosine kinase domain mutants induce two distinct phenotypes in a murine bone marrow transplant model. Blood, 105, 4792 4799.
11. Knapper, S., Mills, K.I., Gilkes, A.F., Austin, S.J., Walsh, V. Burnett, A.K. (2006a) The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood, 108, 3494 3503.
12. Knapper, S., Burnett, A.K., Littlewood, T., Kell, W.J., Agrawal, S., Chopra, R., Clark, R., Levis, M.J. Small, D. (2006b) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 108, 3262 3270.
13. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752 1759.
14. Kottaridis, P.D., Gale, R.E., Langabeer, S.E., Frew, M.E., Bowen, D.T. Linch, D.C. (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood, 100, 2393 2398.
15. Kottaridis, P.D., Gale, R.E. Linch, D.C. (2003) Flt3 mutations and leukaemia. British Journal of Haematology, 122, 523 538.
16. Levis, M., Allebach, J., Tse, K.F., Zheng, R., Baldwin, B.R., Smith, B.D., Jones-Bolin, S., Ruggeri, B., Dionne, C. Small, D. (2002) A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 99, 3885 3891.
17. Mead, A.J., Linch, D.C., Hills, R.K., Wheatley, K., Burnett, A.K. Gale, R.E. (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood, 110, 1262 1270.
18. Meshinchi, S., Alonzo, T.A., Stirewalt, D.L., Zwaan, M., Zimmerman, M., Reinhardt, D., Kaspers, G.J., Heerema, N.A., Gerbing, R., Lange, B.J. Radich, J.P. (2006) Clinical implications of FLT3 mutations in pediatric AML. Blood, 108, 3654 3661.
19. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T. Misawa, S. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911 1918.
20. Raghavan, M., Lillington, D.M., Skoulakis, S., Debernardi, S., Chaplin, T., Foot, N.J., Lister, T.A. Young, B.D. (2005) Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Research, 65, 375 378.
21. Sargin, B., Choudhary, C., Crosetto, N., Schmidt, M.H., Grundler, R., Rensinghoff, M., Thiessen, C., Tickenbrock, L., Schwable, J., Brandts, C., August, B., Koschmieder, S., Bandi, S.R., Duyster, J., Berdel, W.E., Muller-Tidow, C., Dikic, I. Serve, H. (2007) Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood, 110, 1004 1012.
22. Schnittger, S., Schoch, C., Kern, W., Hiddemann, W. Haferlach, T. (2004) FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematologica, 112, 68 78.
23. Shih, L.Y., Huang, C.F., Wu, J.H., Lin, T.L., Dunn, P., Wang, P.N., Kuo, M.C., Lai, C.L. Hsu, H.C. (2002) Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood, 100, 2387 2392.
24. Smith, B.D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K.M., Dauses, T., Allebach, J. Small, D. (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood, 103, 3669 3676.
25. Stone, R.M. (2007) Novel therapeutic agents in acute myeloid leukemia. Experimental Hematology, 35, 163 166.
26. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326 4335.
27. Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., Carroll, A.J., Mrozek, K., Vardiman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 7233 7239.
28. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R. Naoe, T. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97, 2434 2439.
29. Zheng, R., Levis, M., Piloto, O., Brown, P., Baldwin, B.R., Gorin, N.C., Beran, M., Zhu, Z., Ludwig, D., Hicklin, D., Witte, L., Li, Y. Small, D. (2004) FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood, 103, 267 274.